Effect of non-Hodgkin lymphoma on survival in patients with malignant fibrous histiocytoma, Kaposi sarcoma, and sebaceous carcinoma

A seer population-based study

Jerry D. Brewer, Tait D. Shanafelt, James R Cerhan, Timothy G. Call, Amy L. Weaver, Clark C. Otley

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To quantify the behavior of dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), Kaposi sarcoma (KS), and sebaceous carcinoma (SC) in patients with a history of non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: Subjects with a diagnosis of DFSP, MFH, KS, or SC between 1990 and 2006 were identified in the Surveillance, Epidemiology, and End Results Program database. For each skin cancer type, the standardized mortality ratio (SMR) for death due to any cause and death due to skin cancer was estimated. RESULTS: From 1990 through 2006, 25,357 skin cancers were identified: 4,192 DFSP, 6,412 MFH, 10,543 KS, and 4,222 SC. For patients with a history of non-CLL NHL, SMRs for death due to any cause were 1.45 (95% confidence interval [CI], 1.03-2.04; p = 0.04) for MFH, 2.90 (95% CI, 2.50-3.36; p <0.001) for KS, and 3.25 (95% CI, 1.84-5.75; p <0.001) for SC and SMRs for death due to skin cancer were 0.55 (95% CI, 0.23-1.31; p = 0.18) for MFH, 2.93 (95% CI, 2.49-3.43; p <0.001) for KS, and 4.07 (95% CI, 1.28-12.94; p <0.001) for SC. CONCLUSION: Among patients with KS and SC, patients with a history of non-CLL NHL have a greater risk of overall and cause-specific death than expected.

Original languageEnglish (US)
Pages (from-to)S32-S39
JournalDermatologic Surgery
Volume42
DOIs
StatePublished - 2016

Fingerprint

Malignant Fibrous Histiocytoma
Kaposi's Sarcoma
Non-Hodgkin's Lymphoma
Skin Neoplasms
Dermatofibrosarcoma
Confidence Intervals
Carcinoma
Survival
Population
Cause of Death
SEER Program
Databases
Mortality

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Effect of non-Hodgkin lymphoma on survival in patients with malignant fibrous histiocytoma, Kaposi sarcoma, and sebaceous carcinoma : A seer population-based study. / Brewer, Jerry D.; Shanafelt, Tait D.; Cerhan, James R; Call, Timothy G.; Weaver, Amy L.; Otley, Clark C.

In: Dermatologic Surgery, Vol. 42, 2016, p. S32-S39.

Research output: Contribution to journalArticle

@article{726c4871e2ca4d9bb458861d2b92a937,
title = "Effect of non-Hodgkin lymphoma on survival in patients with malignant fibrous histiocytoma, Kaposi sarcoma, and sebaceous carcinoma: A seer population-based study",
abstract = "OBJECTIVE: To quantify the behavior of dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), Kaposi sarcoma (KS), and sebaceous carcinoma (SC) in patients with a history of non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: Subjects with a diagnosis of DFSP, MFH, KS, or SC between 1990 and 2006 were identified in the Surveillance, Epidemiology, and End Results Program database. For each skin cancer type, the standardized mortality ratio (SMR) for death due to any cause and death due to skin cancer was estimated. RESULTS: From 1990 through 2006, 25,357 skin cancers were identified: 4,192 DFSP, 6,412 MFH, 10,543 KS, and 4,222 SC. For patients with a history of non-CLL NHL, SMRs for death due to any cause were 1.45 (95{\%} confidence interval [CI], 1.03-2.04; p = 0.04) for MFH, 2.90 (95{\%} CI, 2.50-3.36; p <0.001) for KS, and 3.25 (95{\%} CI, 1.84-5.75; p <0.001) for SC and SMRs for death due to skin cancer were 0.55 (95{\%} CI, 0.23-1.31; p = 0.18) for MFH, 2.93 (95{\%} CI, 2.49-3.43; p <0.001) for KS, and 4.07 (95{\%} CI, 1.28-12.94; p <0.001) for SC. CONCLUSION: Among patients with KS and SC, patients with a history of non-CLL NHL have a greater risk of overall and cause-specific death than expected.",
author = "Brewer, {Jerry D.} and Shanafelt, {Tait D.} and Cerhan, {James R} and Call, {Timothy G.} and Weaver, {Amy L.} and Otley, {Clark C.}",
year = "2016",
doi = "10.1097/DSS.0000000000000520",
language = "English (US)",
volume = "42",
pages = "S32--S39",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effect of non-Hodgkin lymphoma on survival in patients with malignant fibrous histiocytoma, Kaposi sarcoma, and sebaceous carcinoma

T2 - A seer population-based study

AU - Brewer, Jerry D.

AU - Shanafelt, Tait D.

AU - Cerhan, James R

AU - Call, Timothy G.

AU - Weaver, Amy L.

AU - Otley, Clark C.

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: To quantify the behavior of dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), Kaposi sarcoma (KS), and sebaceous carcinoma (SC) in patients with a history of non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: Subjects with a diagnosis of DFSP, MFH, KS, or SC between 1990 and 2006 were identified in the Surveillance, Epidemiology, and End Results Program database. For each skin cancer type, the standardized mortality ratio (SMR) for death due to any cause and death due to skin cancer was estimated. RESULTS: From 1990 through 2006, 25,357 skin cancers were identified: 4,192 DFSP, 6,412 MFH, 10,543 KS, and 4,222 SC. For patients with a history of non-CLL NHL, SMRs for death due to any cause were 1.45 (95% confidence interval [CI], 1.03-2.04; p = 0.04) for MFH, 2.90 (95% CI, 2.50-3.36; p <0.001) for KS, and 3.25 (95% CI, 1.84-5.75; p <0.001) for SC and SMRs for death due to skin cancer were 0.55 (95% CI, 0.23-1.31; p = 0.18) for MFH, 2.93 (95% CI, 2.49-3.43; p <0.001) for KS, and 4.07 (95% CI, 1.28-12.94; p <0.001) for SC. CONCLUSION: Among patients with KS and SC, patients with a history of non-CLL NHL have a greater risk of overall and cause-specific death than expected.

AB - OBJECTIVE: To quantify the behavior of dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), Kaposi sarcoma (KS), and sebaceous carcinoma (SC) in patients with a history of non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: Subjects with a diagnosis of DFSP, MFH, KS, or SC between 1990 and 2006 were identified in the Surveillance, Epidemiology, and End Results Program database. For each skin cancer type, the standardized mortality ratio (SMR) for death due to any cause and death due to skin cancer was estimated. RESULTS: From 1990 through 2006, 25,357 skin cancers were identified: 4,192 DFSP, 6,412 MFH, 10,543 KS, and 4,222 SC. For patients with a history of non-CLL NHL, SMRs for death due to any cause were 1.45 (95% confidence interval [CI], 1.03-2.04; p = 0.04) for MFH, 2.90 (95% CI, 2.50-3.36; p <0.001) for KS, and 3.25 (95% CI, 1.84-5.75; p <0.001) for SC and SMRs for death due to skin cancer were 0.55 (95% CI, 0.23-1.31; p = 0.18) for MFH, 2.93 (95% CI, 2.49-3.43; p <0.001) for KS, and 4.07 (95% CI, 1.28-12.94; p <0.001) for SC. CONCLUSION: Among patients with KS and SC, patients with a history of non-CLL NHL have a greater risk of overall and cause-specific death than expected.

UR - http://www.scopus.com/inward/record.url?scp=84955262456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955262456&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000000520

DO - 10.1097/DSS.0000000000000520

M3 - Article

VL - 42

SP - S32-S39

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

ER -